HIPEC for Peritoneal Mesothelioma: Survival
CRS/HIPEC achieves 53-103 month median survival for peritoneal mesothelioma. 28-year data shows survival curves flatten after year 6, signaling long-term cure.
HIPEC: The Gold Standard for Peritoneal Mesothelioma
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) represents the most effective treatment for peritoneal mesothelioma. Long-term data from high-volume centers now shows that a significant portion of patients can be considered cured.
28-year outcome data:
- Survival curves flatten after postoperative year 6, signaling long-term cure in survivors
- Median survival: 53-103 months depending on tumor factors
- 5-year survival: 47-52% at specialized centers
What Is CRS/HIPEC?
The Procedure
CRS/HIPEC is a two-part surgical treatment:
1. Cytoreductive Surgery (CRS)
- Removal of all visible tumors from the abdominal cavity
- May include removal of affected peritoneum, organs, or organ portions
- Goal: Complete cytoreduction (CC-0 = no visible disease remaining)
2. Heated Intraperitoneal Chemotherapy (HIPEC)
- Immediately follows surgery while abdomen is still open
- Heated chemotherapy (104-109 degrees Fahrenheit) circulated through abdominal cavity
- Duration: 60-120 minutes
- Heat enhances chemotherapy penetration and effectiveness
Why It Works
The combination addresses peritoneal mesothelioma on multiple levels:
- Surgery removes bulk disease that chemotherapy cannot penetrate
- Heat kills microscopic cancer cells and enhances drug absorption
- Direct chemotherapy delivery reaches cells that systemic chemo cannot access
- High drug concentrations possible without systemic toxicity
Survival Outcomes by Center
High-Volume Center Data (28 Years)
A study of 111 consecutive patients treated from 1993-2021 showed:
| Time Point | Median Survival |
|---|---|
| Overall cohort | 3.3 years (39.6 months) |
| If survived 1 year | 4.9 years |
| If survived 3 years | 6.1 years |
| 75th percentile | 10.6 years |
Conditional survival improves significantly for patients who reach post-operative milestones.
Australian Centre Outcomes
Data from 53 months median follow-up:
| Measure | Outcome |
|---|---|
| Median overall survival | 53 months |
| 1-year survival | 76% |
| 3-year survival | 55% |
| 5-year survival | 49% |
Survival by Completeness of Cytoreduction
The degree of tumor removal is the strongest predictor of outcomes:
| CC Score | Definition | Median Survival |
|---|---|---|
| CC-0 | No visible disease | 104 months |
| CC-1 | Residual nodules under 2.5mm | 30 months |
| CC-2 | Residual nodules 2.5mm-2.5cm | 2.7 months |
Complete cytoreduction (CC-0) achieves 8.6 years median survival.
Prognostic Factors
Tumor Burden (PCI Score)
The Peritoneal Cancer Index (PCI) measures disease extent on a 0-39 scale:
| PCI Range | Median Survival |
|---|---|
| 0-20 (low-moderate) | 103 months |
| 21-39 (high) | 33 months |
Other Significant Factors
Favorable factors:
- Complete cytoreduction (CC-0)
- Low PCI score (under 20)
- No lymph node involvement
- Epithelioid cell type
- Low proliferative index
- Negative podoplanin
Unfavorable factors:
- High PCI score
- Incomplete cytoreduction
- Lymph node metastasis
- Sarcomatoid or biphasic histology
- High proliferative markers
Long-Term Survivors: The Cure Signal
Long-term follow-up reveals that patients reaching certain milestones appear to be cured:
| Finding | Data |
|---|---|
| Survival curve plateau | After postoperative year 6 |
| Conditional survival at 1 year | 4.9 years median |
| Conditional survival at 3 years | 6.1 years median |
The overall and conditional survival curves flatten after year 6, which means patients who reach that mark have minimal risk of mesothelioma recurrence and can be considered functionally cured.
Unlike pleural mesothelioma, peritoneal mesothelioma treated with CRS/HIPEC shows a real long-term cure signal. In the largest single-center series, survival curves flatten after year 6, meaning patients who reach that mark appear to be cured.
Recurrence Patterns
A 2025 study in Annals of Surgical Oncology examined recurrence risk:
- Two-thirds of patients experience recurrence at some point
- Recurrence doesn’t preclude additional treatment
- Iterative CRS/HIPEC possible for selected recurrences
- Systemic chemotherapy options available
Options if the Cancer Comes Back
For patients who recur:
- Repeat cytoreduction may be possible
- Second HIPEC in select cases
- Systemic immunotherapy options
- Palliative care for symptom management
Neoadjuvant Therapy: Emerging Approach
A March 2026 study showed that systemic therapy before CRS/HIPEC for high-volume disease is:
- Feasible and safe
- Similar operative times as upfront surgery
- Comparable complication rates
- May improve resectability of initially borderline cases
This approach allows some patients with higher-volume disease to become surgical candidates.
Who Is a Candidate?
Who Benefits Most From CRS/HIPEC
- Diagnosis confirmed as peritoneal mesothelioma
- Low to moderate tumor burden (PCI under 20)
- Good performance status (able to tolerate major surgery)
- No distant metastases
- Epithelioid cell type preferred
When Surgery May Not Be Appropriate
- Very high tumor burden (PCI over 30)
- Poor functional status
- Significant comorbidities
- Certain tumor locations (diffuse small bowel involvement)
- Aggressive sarcomatoid histology
How Centers Decide Who Qualifies
Candidacy is determined through:
- CT/MRI imaging of abdomen and pelvis
- Possible diagnostic laparoscopy
- Assessment of tumor volume and distribution
- Pathology review of biopsy
- Cardiopulmonary evaluation
- Nutritional assessment
Recovery and Expectations
Hospital Stay
- Typical stay: 7-14 days
- ICU monitoring first 1-2 days
- Gradual return of bowel function
- Pain management required
The First Months Home
- Return to light activity: 4-6 weeks
- Full recovery: 2-3 months
- Long-term dietary modifications may be needed
- Regular follow-up imaging required
Potential Complications
CRS/HIPEC is major surgery with potential risks:
- Anastomotic leak
- Infection
- Bowel obstruction
- Kidney effects from chemotherapy
- Blood clots
- Wound healing issues
Complication rates are lower at high-volume specialized centers.
Finding a HIPEC Center
What to Look For
- High case volume (minimum 20-30 cases per year)
- Multidisciplinary team (surgical oncologist, medical oncologist, pathologist)
- Experience with mesothelioma specifically (not just other peritoneal cancers)
- Published outcomes data
Questions to Ask
- How many peritoneal mesothelioma cases have you treated?
- What is your complete cytoreduction rate?
- What is your median survival for mesothelioma specifically?
- What is your complication rate?
- Do you offer repeat surgery for recurrence?
Comparison to Other Treatments
| Treatment | Median Survival |
|---|---|
| CRS/HIPEC (complete cytoreduction) | 53-103 months |
| Systemic chemotherapy alone | 12-14 months |
| Palliative care | 6-9 months |
CRS/HIPEC offers 4-8x longer survival than chemotherapy alone for eligible patients.
Reader Q&A
Frequently Asked Questions
What is the cure rate for CRS/HIPEC?
In the largest single-center series, survival curves flatten after postoperative year 6, meaning patients who reach that mark are considered functionally cured with minimal recurrence risk. Complete cytoreduction (CC-0) achieves 104-month median survival.
How long is recovery from CRS/HIPEC?
Hospital stay is typically 7-14 days. Return to light activity takes 4-6 weeks, with full recovery in 2-3 months. Long-term dietary modifications may be needed.
Who is a good candidate for CRS/HIPEC?
Ideal candidates have peritoneal mesothelioma with low-moderate tumor burden (PCI under 20), good performance status, epithelioid cell type, and no distant metastases. A surgical evaluation at a high-volume center determines candidacy.
What if the cancer recurs after HIPEC?
About two-thirds of patients experience recurrence. Options include repeat cytoreduction, second HIPEC in select cases, systemic immunotherapy, and palliative care. Recurrence doesn’t preclude additional treatment.
What is the life expectancy of someone with peritoneal mesothelioma?
People with peritoneal mesothelioma have an average life expectancy of 53 months with cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC), compared to 6-12 months without treatment. The 5-year survival rate is 65%, rising to about 80% with cytoreduction, HIPEC, and follow-up chemotherapy in eligible cases. Survival varies by cell type, with epithelioid averaging over 31 months and sarcomatoid around 5 months after treatment.
How close are we to a cure for mesothelioma?
No cure exists for mesothelioma as of 2026. Approved first-line treatments include nivolumab plus ipilimumab immunotherapy (FDA-approved, with 3-year PFS of 14% vs. 1% for chemotherapy) and pembrolizumab plus chemotherapy (ORR 22% vs. 6%). Over 80 active clinical trials test emerging therapies like enzyme therapy (ADI-PEG20 extended survival 4-fold at 3 years), cancer vaccines (UV1 doubled response rates), and targeted therapies, with median survival reaching 18+ months in some multimodal approaches. Research shows improved outcomes but no evidence of curative potential yet.